# A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer

> **NCT05482568** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 324 (estimated)

## Conditions studied

- Advanced Non-small Cell Lung Cancer

## Interventions

- **DRUG:** SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316

## Key facts

- **NCT ID:** NCT05482568
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-15
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 324 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05482568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05482568, "A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05482568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*